Safety and Efficacy of IBI306 in HeFH Patients
A Study to Evaluate Safety and Efficacy of IBI306 in Patients With Heterozygous Familial Hypercholesterolemia
Sponsor: Innovent Biologics (Suzhou) Co. Ltd.
This PHASE3 trial investigates Heterozygous Familial Hypercholesterolemia and is currently completed. Innovent Biologics (Suzhou) Co. Ltd. leads this study, which shows 8 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Sep 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2022 — Sep 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Feb 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
▶ Show 3 earlier versions
-
Jan 2021 — Feb 2021 [monthly]
Recruiting PHASE3
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Dec 2019 — Mar 2020 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Innovent Biologics (Suzhou) Co. Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .